ASCO Annual Meeting | Conference

Dr. Vogelzang Discusses the Addition of Chemotherapy to ADT in Men With Prostate Cancer

June 9th 2014

Nicholas J. Vogelzang, MD,discusses results from the phase III CHAARTED (E3805) study that examined the addition of chemotherapy to androgen deprivation therapy (ADT) for the treatment of men with newly diagnosed metastatic, hormone-sensitive prostate cancer.

Dr. Dispenzieri Discusses Anti-CD38 Monoclonal Antibodies in Myeloma

June 6th 2014

Angela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses excitement over the development of CD38-targeted monoclonal antibodies as treatments for patients with multiple myeloma.

Pembrolizumab Induces Robust Responses in PD-L1-positive NSCLC

June 6th 2014

The anti-PD-1 humanized antibody pembrolizumab has robust antitumor activity as a first-line treatment for patients with advanced PD-L1-positive NSCLC.

Dr. Figlin on Advances in Immunotherapy for Kidney Cancer

June 6th 2014

Robert Figlin, MD, FACP, Professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, Cedars-Sinai Medical Center, discusses recent advances in the field of immunotherapy for kidney cancer.

Dr. Berenson Discusses Results from the CHAMPION-1 Trial

June 6th 2014

James R. Berenson, MD, founder, President and Medical and Scientific Director of the Institute for Myeloma and Bone Cancer Research, President of Oncotherapeutics, discusses the dose-escalation portion of the phase I/II CHAMPION-1 study looking at weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.

Necitumumab Delivers Rare Survival Benefit in Squamous NSCLC

June 6th 2014

Adding necitumumab to standard of care with gemcitabine-cisplatin significantly improves survival compared with chemotherapy alone as first-line treatment in patients with stage IV non–small-cell lung cancer of squamous histology.

Dr. Ramalingam on the Results of the Phase III REVEL Study in NSCLC

June 5th 2014

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses the results of the phase III REVEL study in NSCLC.

Dr. Wolchok on Ipilimumab After Complete Resection of Stage III Melanoma

June 5th 2014

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, Giant of Cancer Care, discusses the initial efficacy and safety results from the EORTC 18071 phase III trial, which looked at ipilimumab versus placebo after complete resection of stage III melanoma.

Dr. Curran on the Effect of Clinical Trial Enrollment on NSCLC Patients

June 4th 2014

Walter J. Curran, Jr, MD, discusses a report that examined the effect of institutional clinical trial enrollment volume on survival of patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation.

Dr. Younes on R-CHOP in Combination with Ibrutinib in DLBCL

June 3rd 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses a phase III study of ibrutinib in combination R-CHOP in patients with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma.

Panobinostat Combination Improves PFS in Multiple Myeloma

June 3rd 2014

Combining panobinostat (LBH589) with bortezomib and dexamethasone delayed disease progression by 3.9 months over bortezomib and dexamethasone alone in patients with relapsed or relapsed and refractory multiple myeloma.

Anti-CD38 Antibody Generates Excitement in Multiple Myeloma

June 3rd 2014

The CD38-specific monoclonal antibody SAR650984 demonstrated encouraging efficacy as a monotherapy and in combination with dexamethasone and lenalidomide without reaching a maximum tolerated dose in patients with heavily pretreated multiple myeloma.

Follow-up of Concurrent Immunotherapies Shows Unprecedented Survival Rate in Melanoma

June 3rd 2014

Long-term follow-up results demonstrated nearly doubled median OS with the combination of ipilimumab and nivolumab compared with either agent alone.

Dr. Spigel Discusses MPDL3280A Development in Lung Cancer

June 3rd 2014

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses current trials involving MPDL3280A in lung cancer.

'Smart' Alkylator TH-302 Shows Clinical Benefit in Early Multiple Myeloma Trial

June 2nd 2014

The addition of the investigational hypoxia-targeted drug TH-302 to dexamethasone has demonstrated beneficial activity and a manageable adverse event profile in the treatment of patients with relapsed/refractory multiple myeloma.

Novel Rituximab Combinations Highly Effective in CLL

June 2nd 2014

The novel agents idelalisib and ABT-199 in combination with rituximab have demonstrated impressive activity with manageable toxicity for patients with relapsed or refractory chronic lymphocytic leukemia.

Practice-Changing Data Revealed for Premenopausal HR+ Breast Cancer

June 2nd 2014

A joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptor–positive (HR+) breast cancer demonstrated that adjuvant use of the aromatase inhibitor (AI), exemestane, reduced relative risk of developing subsequent invasive cancer by 28% compared with tamoxifen when both agents were combined with ovarian function suppression (OFS).

T-VEC Combinations, Monotherapy Intriguing in Unresectable Melanoma

June 2nd 2014

The intratumoral injection talimogene laherparepvec demonstrated promise in combinations and utility as a monotherapy in certain subsets of patients with unresectable melanoma.

HPV-Targeting Immunotherapy Shows Early Promise in Cervical Cancer

June 2nd 2014

Two patients with metastatic cervical cancer achieved durable complete responses that have so far lasted from 15 to 22 months through an adoptive T-cell therapy (ACT) targeting the human papillomavirus (HPV) in a study that researchers say supports the concept that the experimental immunotherapy approach may be beneficial in a variety of tumor types.

New Study Findings Confirm Pembrolizumab's Durable Responses in Metastatic Melanoma

June 2nd 2014

The anti-PD 1 checkpoint inhibitor, pembrolizumab, continues to deliver impressive results in patients with advanced melanoma-producing long-lasting responses and improved overall survival, regardless of whether patients have been previously treated with ipilimumab.

NEXT PAGE
PREVIOUS PAGE